Heart failure & cardiomyopathies
DIGitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure (DIGIT-HF): Baseline Characteristics Compared to Recent Randomized Controlled Heart Failure Trials
Authors' conclusion
Patients included in DIGIT-HF display a more severe HF symptom burden and higher rates of ICD/CRT implants compared to participants in recent HFrEF trials, while pharmacotherapy was largely similar.
Study context
- Population
- Symptomatic HFrEF (NYHA II and LVEF ≤30%, or NYHA III–IV and LVEF ≤40%)ITT population
- Participants
- 1,212 participants
- Comparison
- DIGIT-HF baseline characteristics vs recent HFrEF trials
Methodological detailsbaseline characteristics report, double-blind, placebo-controlled, multicentre
- Baseline characteristics report
- Double-blind
- Placebo-controlled
- Multicentre
Primary result
As reported in the abstract
Baseline characteristics (ITT population)
- Mean age (years), mean ± SD
- 66 ± 11
- Women
- 20%
- Mean LVEF, mean ± SD
- 29 ± 7%
- NYHA class II, III, IV
- 30%, 66% and 4%
- AF
- 27%
- Beta-blockers
- 96%
- ACEi/ARB/ARNI
- 95%
- MRA
- 76%
- Diuretics
- 87%
- ARNI
- 40%
- SGLT2 inhibitors
- 19%
- Ivabradine
- 9%
- Implantable cardioverter-defibrillator (ICD)
- 64%
- Cardiac resynchronization therapy (CRT)
- 25%
Original publication
DIGitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure (DIGIT-HF): Baseline Characteristics Compared to Recent Randomized Controlled Heart Failure Trials. Eur J Heart Fail. Published 19 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →